Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1990 Dec;87(23):9368–9372. doi: 10.1073/pnas.87.23.9368

Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine.

R Albores 1, E J Neafsey 1, G Drucker 1, J Z Fields 1, M A Collins 1
PMCID: PMC55166  PMID: 2251279

Abstract

Mitochondrial accumulation and respiratory inhibition are critical steps in the actions of N-methyl-4-phenylpyridinium ion (MPP+), the toxic metabolite of the parkinsonism-inducing agent, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. We examined the respiratory characteristics of 2-methylated beta-carbolines (2-Me beta Cs) and 2-methylated 3,4-dihydro-beta-carbolines (2-MeDH beta Cs), which encompass the MPP+ structure. As indoleamine derivatives, they could have endogenous roles in idiopathic parkinsonism. With rat liver mitochondria, the order for inhibition of NAD(+)-linked O2 consumption (6-min preincubations) was as follows: MPP+ = 2-methylharmine greater than 2-methylharmol = 2-methylharmaline much greater than 2-methylharmalol greater than 2-methylnorharman greater than 6-OH-2-methylharmalan much greater than 2-methylharman. Similar to MPP+, 2-MeDH beta C/2-Me beta C inhibition was potentiated by tetraphenylboron and reversed by dinitrophenol, consistent with the involvement of cationic forms. However, the participation of neutral forms was indicated by the 2-MeDH beta C/2-Me beta C inhibitory time courses, which were unlike MPP+. The neutral forms probably arise via indolic nitrogen deprotonation because the characteristics of a cationic beta-carboline that cannot N-deprotonate, 2,9-dimethylnorharman, mirrored MPP+ rather than 2-Me beta Cs. Succinate-supported respiration was also significantly blocked by 2-MeDH beta Cs/2-Me beta Cs, but results with tetraphenylboron and 2,9-dimethylnorharman indicated that cationic forms were less important than in the inhibition of NAD(+)-linked respiration. We suggest that the relatively potent inhibition by certain 2-MeDH beta Cs/2-Me beta Cs involves neutral forms for passive mitochondrial entry and cationic as well as neutral forms that act at several respiratory sites. Respiratory inhibition could reasonably underlie the reported neurotoxicity of 2-Me beta Cs.

Full text

PDF
9368

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arora P. K., Riachi N. J., Fiedler G. C., Singh M. P., Abdallah F., Harik S. I., Sayre L. M. Structure-neurotoxicity trends of analogues of 1-methyl-4-phenylpyridinium (MPP+), the cytotoxic metabolite of the dopaminergic neurotoxin MPTP. Life Sci. 1990;46(5):379–390. doi: 10.1016/0024-3205(90)90018-m. [DOI] [PubMed] [Google Scholar]
  2. Barker S. A., Harrison R. E., Monti J. A., Brown G. B., Christian S. T. Identification and quantification of 1,2,3,4-tetrahydro-beta-carboline, 2-methyl-1,2,3,4-tetrahydro-beta-carboline, and 6-methoxy-1,2,3,4-tetrahydro-beta-carboline as in vivo constituents of rat brain and adrenal gland. Biochem Pharmacol. 1981 Jan 1;30(1):9–17. doi: 10.1016/0006-2952(81)90278-1. [DOI] [PubMed] [Google Scholar]
  3. Beck O., Faull K. F., Repke D. B. Rapid hydroxylation of methtryptoline (1-methyltetrahydro-beta-carboline) in rat: identification of metabolites by chiral gas chromatography-mass spectrometry. Naunyn Schmiedebergs Arch Pharmacol. 1986 Jul;333(3):307–312. doi: 10.1007/BF00512946. [DOI] [PubMed] [Google Scholar]
  4. Bosin T. R., Faull K. F. Harman in alcoholic beverages: pharmacological and toxicological implications. Alcohol Clin Exp Res. 1988 Oct;12(5):679–682. doi: 10.1111/j.1530-0277.1988.tb00264.x. [DOI] [PubMed] [Google Scholar]
  5. Bosin T. R., Faull K. F. Indole derivatization procedures for electron capture negative chemical ionization mass spectrometry: identification of 1-methyl-1,2,3,4-tetrahydro-beta-carboline in rat brain and lung. Biomed Environ Mass Spectrom. 1989 Apr;18(4):247–252. doi: 10.1002/bms.1200180407. [DOI] [PubMed] [Google Scholar]
  6. Collins M. A., Neafsey E. J. Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism? Neurosci Lett. 1985 Apr 9;55(2):179–184. doi: 10.1016/0304-3940(85)90016-3. [DOI] [PubMed] [Google Scholar]
  7. Drucker G., Raikoff K., Neafsey E. J., Collins M. A. Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products. Brain Res. 1990 Feb 12;509(1):125–133. doi: 10.1016/0006-8993(90)90318-6. [DOI] [PubMed] [Google Scholar]
  8. Godin C. S., Crooks P. A. N-methylation as a toxication route for xenobiotics. II. In vivo formation of N,N'-dimethyl-4,4'-bipyridyl ion (paraquat) from 4,4'-bipyridyl in the guinea pig. Drug Metab Dispos. 1989 Mar-Apr;17(2):180–185. [PubMed] [Google Scholar]
  9. Heikkila R. E., Hwang J., Ofori S., Geller H. M., Nicklas W. J. Potentiation by the tetraphenylboron anion of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its pyridinium metabolite. J Neurochem. 1990 Mar;54(3):743–750. doi: 10.1111/j.1471-4159.1990.tb02314.x. [DOI] [PubMed] [Google Scholar]
  10. Ho B. T., Gardner P. M., Walker K. E. Inhibition of MAO by -carbolinium halides. J Pharm Sci. 1973 Jan;62(1):36–39. doi: 10.1002/jps.2600620105. [DOI] [PubMed] [Google Scholar]
  11. Hoppel C. L., Grinblatt D., Kwok H. C., Arora P. K., Singh M. P., Sayre L. M., Greenblatt D. Inhibition of mitochondrial respiration by analogs of 4-phenylpyridine and 1-methyl-4-phenylpyridinium cation (MPP+), the neurotoxic metabolite of MPTP. Biochem Biophys Res Commun. 1987 Oct 29;148(2):684–693. doi: 10.1016/0006-291x(87)90931-4. [DOI] [PubMed] [Google Scholar]
  12. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  13. Melchior C., Collins M. A. The route and significance of endogenous synthesis of alkaloids in animals. Crit Rev Toxicol. 1982;9(4):313–356. doi: 10.3109/10408448209037496. [DOI] [PubMed] [Google Scholar]
  14. Naoi M., Matsuura S., Takahashi T., Nagatsu T. A N-methyltransferase in human brain catalyses N-methylation of 1,2,3,4-tetrahydroisoquinoline into N-methyl-1,2,3,4-tetrahydroisoquinoline, a precursor of a dopaminergic neurotoxin, N-methylisoquinolinium ion. Biochem Biophys Res Commun. 1989 Jun 30;161(3):1213–1219. doi: 10.1016/0006-291x(89)91371-5. [DOI] [PubMed] [Google Scholar]
  15. Neafsey E. J., Drucker G., Raikoff K., Collins M. A. Striatal dopaminergic toxicity following intranigral injection in rats of 2-methyl-norharman, a beta-carbolinium analog of N-methyl-4-phenylpyridinium ion (MPP+). Neurosci Lett. 1989 Nov 6;105(3):344–349. doi: 10.1016/0304-3940(89)90645-9. [DOI] [PubMed] [Google Scholar]
  16. Nicklas W. J., Vyas I., Heikkila R. E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985 Jul 1;36(26):2503–2508. doi: 10.1016/0024-3205(85)90146-8. [DOI] [PubMed] [Google Scholar]
  17. Ohkubo S., Hiraro T., Oka K. Methyltetrahydro-beta-carbolines and Parkinson's disease. Lancet. 1985 Jun 1;1(8440):1272–1273. doi: 10.1016/s0140-6736(85)92338-4. [DOI] [PubMed] [Google Scholar]
  18. Peura P., Johnson J. V., Yost R. A., Faull K. F. Concentrations of tryptoline and methtryptoline in rat brain. J Neurochem. 1989 Mar;52(3):847–852. doi: 10.1111/j.1471-4159.1989.tb02531.x. [DOI] [PubMed] [Google Scholar]
  19. Ramsay R. R., Dadgar J., Trevor A., Singer T. P. Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci. 1986 Aug 18;39(7):581–588. doi: 10.1016/0024-3205(86)90037-8. [DOI] [PubMed] [Google Scholar]
  20. Ramsay R. R., McKeown K. A., Johnson E. A., Booth R. G., Singer T. P. Inhibition of NADH oxidation by pyridine derivatives. Biochem Biophys Res Commun. 1987 Jul 15;146(1):53–60. doi: 10.1016/0006-291x(87)90689-9. [DOI] [PubMed] [Google Scholar]
  21. Ramsay R. R., Mehlhorn R. J., Singer T. P. Enhancement by tetraphenylboron of the interaction of the 1-methyl-4-phenylpyridinium ion (MPP+) with mitochondria. Biochem Biophys Res Commun. 1989 Mar 31;159(3):983–990. doi: 10.1016/0006-291x(89)92205-5. [DOI] [PubMed] [Google Scholar]
  22. Ramsay R. R., Salach J. I., Singer T. P. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem Biophys Res Commun. 1986 Jan 29;134(2):743–748. doi: 10.1016/s0006-291x(86)80483-1. [DOI] [PubMed] [Google Scholar]
  23. Ramsay R. R., Youngster S. K., Nicklas W. J., McKeown K. A., Jin Y. Z., Heikkila R. E., Singer T. P. Structural dependence of the inhibition of mitochondrial respiration and of NADH oxidase by 1-methyl-4-phenylpyridinium (MPP+) analogs and their energized accumulation by mitochondria. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9168–9172. doi: 10.1073/pnas.86.23.9168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rollema H., Booth R. G., Castagnoli N., Jr In vivo dopaminergic neurotoxicity of the 2-beta-methylcarbolinium ion, a potential endogenous MPP+ analog. Eur J Pharmacol. 1988 Aug 9;153(1):131–134. doi: 10.1016/0014-2999(88)90597-3. [DOI] [PubMed] [Google Scholar]
  25. Rommelspacher H., Nanz C., Borbe H. O., Fehske K. J., Müller W. E., Wollert U. 1-Methyl-beta-carboline (harmane), a potent endogenous inhibitor of benzodiazepine receptor binding. Naunyn Schmiedebergs Arch Pharmacol. 1980 Oct;314(1):97–100. doi: 10.1007/BF00498436. [DOI] [PubMed] [Google Scholar]
  26. Sayre L. M. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Lett. 1989 Aug;48(2):121–149. doi: 10.1016/0378-4274(89)90168-9. [DOI] [PubMed] [Google Scholar]
  27. Sayre L. M., Wang F., Hoppel C. L. Tetraphenylborate potentiates the respiratory inhibition by the dopaminergic neurotoxin MPP+ in both electron transport particles and intact mitochondria. Biochem Biophys Res Commun. 1989 Jun 15;161(2):809–818. doi: 10.1016/0006-291x(89)92672-7. [DOI] [PubMed] [Google Scholar]
  28. Schouten M. J., Bruinvels J. Endogenously formed norharman (beta-carboline) in platelet rich plasma obtained from porphyric rats. Pharmacol Biochem Behav. 1986 May;24(5):1219–1223. doi: 10.1016/0091-3057(86)90174-7. [DOI] [PubMed] [Google Scholar]
  29. Singh Y., Bhatnagar R., Sidhu G. S., Batra J. K., Krishna G. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine inhibits proton motive force in energized liver mitochondria. Arch Biochem Biophys. 1989 May 15;271(1):217–222. doi: 10.1016/0003-9861(89)90272-5. [DOI] [PubMed] [Google Scholar]
  30. Susilo R., Damm H., Rommelspacher H., Höfle G. Biotransformation of 1-methyl-1,2,3,4-tetrahydro-beta-carboline-1-carboxylic acid to harmalan, tetrahydroharman and harman in rats. Neurosci Lett. 1987 Oct 29;81(3):325–330. doi: 10.1016/0304-3940(87)90404-6. [DOI] [PubMed] [Google Scholar]
  31. Tanner C. M. The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci. 1989 Feb;12(2):49–54. doi: 10.1016/0166-2236(89)90135-5. [DOI] [PubMed] [Google Scholar]
  32. Testa B., Naylor R., Costall B., Jenner P., Marsden C. D. Does an endogenous methylpyridinium analogue cause Parkinson's disease? J Pharm Pharmacol. 1985 Sep;37(9):679–680. doi: 10.1111/j.2042-7158.1985.tb05116.x. [DOI] [PubMed] [Google Scholar]
  33. Tweedie D. J., Burke M. D. Metabolism of the beta-carbolines, harmine and harmol, by liver microsomes from phenobarbitone- or 3-methylcholanthrene-treated mice. Identification and quantitation of two novel harmine metabolites. Drug Metab Dispos. 1987 Jan-Feb;15(1):74–81. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES